Home | Dendrogenix

Dendrogenix

Dendrogenix is a Belgium based biotech company founded in 2018 to develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology.
Dendrogenins

Dendrogenins are cholesterol derivatives which stimulate cell differentiation in the immune and nervous system and induce the growth of dendrites on dendritic cell and neuron precursors.

On that basis, Dendrogenix has developed this family for new therapies in therapeutic areas with unmet needs including neurological diseases.

DISCOVER NOW
Dendrogenix

NEURON HEALING FOR BETTER LIVING
Dendrogenix

NEURON HEALING FOR BETTER LIVING

|

COMPANY

Established in 2018, Dendrogenix is a Belgian biopharmaceutical company based in Liège.

Dendrogenix is specialized in the development of innovative drugs called Dendrogenins, which are small molecules with high therapeutic potential.

Dendrogenix is dedicated to the preclinical and clinical development of Dendrogenins, mainly in the field of neuronal dysfunction.

Dendrogenix focuses primarily on the area of auditory degeneration for which there are no approved drugs yet.

TECHNOLOGY

Dendrogenix has developed international research partnerships with leading players in the field of deafness and neurology, including world-renowned academic centers such as the GIGA-Neurosciences at the University of Liège, and the University of Tübingen in Germany.

TEAM

Dendrogenix currently employs around 20 people, including doctors in chemistry and biology as well as consultants who are experts in preclinical and clinical pharmaceutical regulatory development.